Background: Selinexor is a nuclear exportin-1 (XPO1) inhibitor used for the treatment of acute myeloid leukemia (AML) patients. Selinexor is administered as a monotherapy or in combination with standard chemotherapy. However, the efficacy and
Search Results
CLO24-083: Efficacy of Selinexor in Acute Myeloid Leukemia: A Systematic Review and Meta-Analysis
Junaid Anwar, Muhammad Haseeb, Anusha Baddam, Salma Saidahmed, Binayak Singh, Roshan, Zahoor Ahmed, Ahmed Abdelhakeem, Kachhadia Meet, Raza Zarrar, and Tahir Naqvi
CLO24-060: Organomegalies as a Predictive Indicator of Leukemia Cutis in the Patients With Acute Myeloid Leukemia
Chalothorn Wannaphut, Chanakarn Kanitthamniyom, Penvadee Pattanaprichakul, Smith Kungwankiatichai, and Weerapat Owattanapanich
Leukemia cutis (LC) is an extramedullary acute myeloid leukemia (AML) infiltrate. No research has outlined the clinical characteristics and outcomes of Thai patients diagnosed with AML who exhibit LC. We conducted a 7-year retrospective case
NCCN Debuts New Guidelines for Myeloproliferative Neoplasms
Ruben A. Mesa
leukemias that can progress to acute myeloid leukemia (AML) and affect patients in a variety of ways. MPNs are largely driven by key molecular abnormalities, and although they share many features with myelodysplastic syndromes and chronic myeloid leukemia
New Therapies for Ovarian Cancer
Deborah K. Armstrong
common, but high grades are not. Figure 2. Managing PARPi toxicities: guidelines from Dr. Armstrong's practice. Abbreviations: AML/MDS, acute myeloid leukemia/myelodysplastic syndromes; BP, blood pressure; LFTs, liver function tests; PARPi, PARP
CLO22-037: Tumor Lysis Syndrome and Infectious Complications During Induction With Venetoclax Combined With Azacitidine or Decitabine in Patients With Acute Myeloid Leukemia
Sankalp Arora, Carl Zainaldin, Srilakshmi Bathini, Udita Gupta, Sarah Worth, Kimo Bachiashvili, Ravi Bhatia, Kelly Godby, Omer Jamy, Sravanti Rangaraju, Barry Diamond, Josh D. Oliver, Donna Salzman, Antonio Di Stasi, and Pankit Vachhani
BACKGROUND : Venetoclax in combination with azacitidine or decitabine(HMA+Ven)is the standard-of-care treatment for older adults(≥75 years) or those with comorbidities precluding intensive induction therapy in newly diagnosed acute myeloid
EPR24-100: A Comparison of Somatic Mutations and ELN Classification in De Novo Acute Myeloid Leukemia Between Appalachian and Non-Appalachian Kentucky
Zena Chahine, Xitong Zhou, Anna Johnson, Trevor Morris, Ashley Soule, Hiffsa Taj, Claire McAvoy, Chaitanya Iragavarapu, Reinhold Munker, Gregory Monohan, Fevzi Yalniz, Ayman Qasrawi, and Reshma Ramlal
myeloid leukemia (AML) in Appalachian Kentucky (ApK) would have worse outcomes and higher mutational burden compared to patients in non-Appalachian Kentucky (Non-ApK). Methods: A single-center retrospective analysis was done utilizing the Kentucky Cancer
YIA22-001: Development of hKIT Chimeric Antigen Receptor T-Cells as Dual Hematopoietic Stem Cell Transplantation Conditioning and Immunotherapeutic Agents for Cure of Pediatric Acute Myeloid Leukemia
Quenton Rashawn Bubb, Corey Cheung, Gabriel Eduardo Seir,, Leah Swartzrock, Rebecca Richards, Crystal Mackall, and Agnieszka Czechowicz
Acute myeloid leukemia (AML) is a frequent subtype of cancer that affects thousands of children and adults worldwide. Current treatments generally consist of harsh, conventional chemotherapy and/or hematopoietic stem cell transplantation (HSCT
NCCN Task Force Report: Evaluating the Clinical Utility of Tumor Markers in Oncology
Phillip G. Febbo, Marc Ladanyi, Kenneth D. Aldape, Angelo M. De Marzo, M. Elizabeth Hammond, Daniel F. Hayes, A. John Iafrate, R. Kate Kelley, Guido Marcucci, Shuji Ogino, William Pao, Dennis C. Sgroi, and Marian L. Birkeland
Biomarkers in Acute Myeloid Leukemia Assays Currently Used in Cancer Care For each disease considered by the task force, including glioma, breast cancer, colon cancer, lung cancer, prostate cancer, and acute myelogenous leukemia, tabular data
The Role of Myeloid Growth Factors in Acute Leukemia
Martha Wadleigh and Richard M. Stone
previously untreated patients 60 years of age and older with acute myeloid leukemia: Cancer and Leukemia Group B study 9720 . Blood 2002 ; 100 : 1224 – 1232 . 3 Stone RM Berg DT George SL . Granulocyte-macrophage colony-stimulating factor after
Controversies Regarding Use of Myeloid Growth Factors in Leukemia
Jacqueline N. Poston and Pamela S. Becker
Acute Myeloid Leukemia The 2 key goals of myeloid growth factor (MGF) use in the management of acute myeloid leukemia (AML) have been (1) a theoretical benefit for “priming” to improve efficacy of chemotherapy, and (2) reduction of neutropenia
